The evolving profile, role and relevance of the medical director in a pharmaceutical company

Over the last years, operations in Pharmaceutical Companies have become more complex, trying to adapt to new demands of the market environment. Overall, the observed change of paradigm requires adapting, mainly by the setting of new priorities, diversification of investments, cost containment strategies, exploring new markets and developping new sets of skills. In this context, new functions have been created, the relevance of some has diminished, and the importance of others has arisen. Amongst these, the medical structure within a Pharmaceutical Company, increased to meet demands, with companies adopting different models to respond to these needs, and becoming a pillar to the business. Assuming the leading role within a medical department, the medical director function often lies in the shadow. It is a key function within Pharma Industry, either on a country or on a Global basis. It has evolved and changed in the past years to meet the constant demands of a changing environment. The Medical Director is a highly skilled and differeniated professional who provides medical and scientific governance within a Pharmaceutical company, since early stages of drug development and up to loss of exclusivity, not only but also by leading a team of other physicians, pharmacists or life scientists whose functions comprise specificities that the medical director needs to understand, provide input to, oversee and lead. As the organization of Pharmaceutical Companies tends to be different, in accordance to values, culture, markets and strategies, the scope of activities of a Medical Director can be broader or may be limited, depending on size of the organization and governance model, but they must fulfil a large set of requirements in order to leverage impact on internal and internal customers. Key technical competencies for medical directors such as an MD degree, a strong clinical foundation, knowledge of drug development, project and team management experience and written and verbal skills are relatively easy to define, but underlying behavioural competencies are more difficult to ascertain, and these are more often the true predictors of success in the role. Beyond seamless proficiency in technical skills, at this level interpersonal skills become far more important, as they are the driver and the distinctive factor between a good and an excelent medical director. And this has impact in the business and in the people doing it.

Modelo de Kuramoto com campos aleatórios em redes complexas

Neste trabalho é estudado o modelo de Kuramoto num grafo completo, em redes scale-free com uma distribuição de ligações P(q) ~ q-Y e na presença de campos aleatórios com magnitude constante e gaussiana. Para tal, foi considerado o método Ott-Antonsen e uma aproximação "annealed network". Num grafo completo, na presença de campos aleatórios gaussianos, e em redes scale-free com 2 < y < 5 na presença de ambos os campos aleatórios referidos, foram encontradas transições de fase contínuas. Considerando a presença de campos aleatórios com magnitude constante num grafo completo e em redes scale-free com y > 5, encontraram-se transições de fase contínua (h < √2) e descontínua (h > √2). Para uma rede SF com y = 3, foi observada uma transição de fase de ordem infinita. Os resultados do modelo de Kuramoto num grafo completo e na presença de campos aleatórios com magnitude constante foram comparados aos de simulações, tendo-se verificado uma boa concordância. Verifica-se que, independentemente da topologia de rede, a constante de acoplamento crítico aumenta com a magnitude do campo considerado. Na topologia de rede scale-free, concluiu-se que o valor do acoplamento crítico diminui à medida que valor de y diminui e que o grau de sincronização aumenta com o aumento do número médio das ligações na rede. A presença de campos aleatórios com magnitude gaussiana num grafo completo e numa rede scale-free com y > 2 não destrói a transição de fase contínua e não altera o comportamento crítico do modelo de Kuramoto.

Study of tRNA modifying enzymes and codon usage bias in cancer

Recent evidences indicate that tRNA modifications and tRNA modifying enzymes may play important roles in complex human diseases such as cancer, neurological disorders and mitochondrial-linked diseases. We postulate that expression deregulation of tRNA modifying enzymes affects the level of tRNA modifications and, consequently, their function and the translation efficiency of their tRNA corresponding codons. Due to the degeneracy of the genetic code, most amino acids are encoded by two to six synonymous codons. This degeneracy and the biased usage of synonymous codons cause alterations that can span from protein folding to enhanced translation efficiency of a select gene group. In this work, we focused on cancer and performed a meta-analysis study to compare microarray gene expression profiles, reported by previous studies and evaluate the codon usage of different types of cancer where tRNA modifying enzymes were found de-regulated. A total of 36 different tRNA modifying enzymes were found de-regulated in most cancer datasets analyzed. The codon usage analysis revealed a preference for codons ending in AU for the up-regulated genes, while the down-regulated genes show a preference for GC ending codons. Furthermore, a PCA biplot analysis showed this same tendency. We also analyzed the codon usage of the datasets where the CTU2 tRNA modifying enzyme was found deregulated as this enzyme affects the wobble position (position 34) of specific tRNAs. Our data points to a distinct codon usage pattern between up and downregulated genes in cancer, which might be caused by the deregulation of specific tRNA modifying enzymes. This codon usage bias may augment the transcription and translation efficiency of some genes that otherwise, in a normal situation, would be translated less efficiently.